Peptide Side Effects: What to Watch For and When to Call Your Physician

Semaglutide and tirzepatide are the exception: both are FDA-approved finished drug products whose labels carry percentages against placebo. On the approved semaglutide 2.4 mg label the reactions at or above 2% and more frequent than placebo were nausea 44% versus 16%, diarrhea 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11%, abdominal pain 20% versus 10%, then headache 14%, fatigue 11%, dyspepsia 9% and hair loss 3%. The approved tirzepatide label shows the same pattern lower — nausea 25–29%, diarrhea 19–23%, constipation 11–17%, vomiting 8–13%, injection-site reactions 6–8% — and states that most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time. That clause is the most useful single fact on this page. The anchor trials are STEP 1 in the New England Journal of Medicine in 2021 and SURMOUNT-1 in 2022. Pepti supplies compounded semaglutide and tirzepatide: a label describes the molecule, not the vial.

Tesamorelin is itself approved for a specific HIV-related indication, and its label carries a table from 543 treated patients: injection-site reactions 17% versus 6% on placebo, arthralgia 13% versus 11%, myalgia and peripheral edema 6% versus 2%, paresthesia 5% versus 2%, carpal tunnel syndrome and joint swelling 1% each versus none, and 5% reaching an HbA1c of 6.5% or higher versus 1%. That is the whole growth-hormone-axis profile in one place. The approved somatropin labels describe the same cluster and call fluid retention dose dependent in adults, and a 2007 systematic review in the Annals of Internal Medicine found the same grouping in healthy older adults. SS-31 — elamipretide, studied in MMPOWER-3 in Neurology in 2023 — carries an approved rare-disease label whose reactions are almost entirely local.

For most of the rest — BPC-157, KPV, GHK-Cu, MOTS-c, epithalon, DSIP — there are no randomized human safety trials and nobody is counting adverse events at scale. What exists is animal and cell research plus prescriber experience. A short list of reported effects is not proof of a short reality; it means detection is weak. TB-500 is a partial exception, with one randomized placebo-controlled intravenous study of its parent molecule in healthy volunteers in 2010, as are selank and semax with Russian clinical programs behind them.

Redness, itching, tenderness or firmness where you injected. It is tissue responding to a needle and a volume of fluid rather than to the molecule, which is why it appears on every injectable here including those with approved labels — 6–8% on tirzepatide, 17% on tesamorelin, and in every treated patient in the small elamipretide study. Settling within a day or two without spreading is expected.

This separates a non-event from a same-day message. A lump that appears as you inject and softens over a day or two is fluid in the tissue. A lump appearing two or three days later that feels warm, spreads, or hurts more each day is a different thing. Repeated injection into one spot also builds a thickened area over months; consensus recommendations on injection-site lipohypertrophy in Diabetes Research and Clinical Practice in 2026 identify failure to rotate as the dominant modifiable cause. How to inject peptides safely covers it.

Stinging during the push is usually cold solution or speed. GHK-Cu stings more than most because of the copper complex, and its blue-green color with a faint temporary mark at the site comes from the copper rather than a fault. NAD+ produces flushing, a warm chest and mild nausea in proportion to how fast it goes in. Flushing minutes after a growth-axis dose is vasodilatory and passes, and evening dosing commonly produces vivid dreams. Mild fatigue or headache in the first fortnight appears across almost every category; on a GLP-1 it is frequently a consequence of eating and drinking far less rather than of the drug.

Sermorelin, CJC-1295 / ipamorelin and tesamorelin prompt your own pituitary to release growth hormone — sermorelin and tesamorelin as GHRH analogs, ipamorelin through the ghrelin receptor. Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006 documented sustained growth hormone and IGF-1 elevation from CJC-1295 in healthy adults; Raun's 1998 paper in the European Journal of Endocrinology established ipamorelin as a selective secretagogue. Because the mechanism is real, the excess-growth-hormone syndrome is real too. Increased hunger belongs here, since that is what a ghrelin-receptor agonist does.

Puffy hands, rings that no longer fit, ankles that mark when pressed, a stiff first hour and aching joints. On the tesamorelin label these are arthralgia, peripheral edema, myalgia and joint swelling, all above placebo, and the somatropin labels call fluid retention dose dependent. Dose dependent is the operative phrase: the symptom tracks the amount, and the amount is adjustable.

Tingling, numbness or pins and needles in the hands, often worst overnight or on waking. This is soft-tissue swelling compressing the median nerve at the wrist, which is why it belongs with fluid retention rather than being treated as a separate nerve problem. Carpal tunnel syndrome and paresthesia both appear on the tesamorelin label above placebo, and the 2007 Annals of Internal Medicine review found the same. It generally resolves when the dose comes down; tingling that does not belongs in tier three.

Growth hormone opposes insulin, which is why fasting glucose is on the panel and why the somatropin labels instruct periodic glucose monitoring in everyone treated. IGF-1 is the marker that integrates a pulsatile hormone: the approved tesamorelin label instructs monitoring it, considering discontinuation for persistent elevation, and reports 47% of treated patients exceeding two standard deviation scores at 26 weeks. The number usually moves before your hands start tingling, which is the argument for at-home blood testing. The logic is sharper for IGF-1 LR3, which supplies the growth factor directly: the approved IGF-1 label carries hypoglycemia as its principal warning, so on IGF-1 LR3, feeling shaky, sweaty or confused after a dose is a blood-sugar event rather than a peptide quirk.

On semaglutide and tirzepatide the signal is gastrointestinal and timed. Nausea arriving two or three days after a step up and fading over the following week is the expected shape; nausea getting worse instead of better, or stopping you keeping fluids down, is not. On the melanocortin peptides the signal is nausea and flushing: the approved bremelanotide label reports nausea in 40% of patients receiving up to eight doses a month, improving for most with the second dose. That label's transient blood-pressure effect is why PT-141 is a blood-pressure conversation with your physician first.

Acute pancreatitis appears in the warnings of both approved GLP-1 labels and both instruct prompt discontinuation if it is suspected; the semaglutide label describes persistent severe abdominal pain, sometimes radiating to the back, which may or may not come with vomiting. Acute gallbladder disease is a separate warning on both, and rapid weight loss is itself a gallstone risk factor. Pain under the right ribs, particularly with fever or yellowing, is the gallbladder pattern.

Both approved GLP-1 labels carry acute kidney injury from volume depletion as a warning, because someone who cannot keep fluids down becomes dehydrated. Both also warn that combining a GLP-1 with insulin or an insulin secretagogue raises the risk of hypoglycemia and that those doses may need reducing — a prescriber decision made in advance. Separately: an injection site that is hot, spreading, or more painful on day three than day one is infection rather than irritation. The rule is direction of travel, not severity at one moment.

On GHK-Cu, persistent nausea and vomiting with abdominal pain or yellowing of the skin or eyes suggests copper accumulation rather than a passing dose effect, and it means stopping and calling. Vision change has its own row because the approved semaglutide label carries diabetic retinopathy complications as a warning in people with type 2 diabetes and a retinopathy history, and the somatropin labels carry intracranial hypertension, usually within the first eight weeks. On lumps and moles: the approved tesamorelin label is contraindicated in active malignancy and instructs discontinuation on evidence of recurrence, because the mechanism releases a growth factor. On Melanotan II the monitoring is dermatological: a 2017 review in the International Journal of Dermatology and case reports in Dermatology describe changes in pigmented lesions, which is why a physician prescribing Melanotan II will want existing moles documented and any change reported.

Injection-site redness, itching, tenderness and a small firm lump are the usual reports. Mild fatigue or headache in the first week or two is described. Serious effects are not commonly reported, with the standard caveat that adverse-event reporting for compounded preparations is thinner than for approved drugs. BPC-157 has no randomized human safety trial; the published work is animal and cell research describing a wide margin between effective doses and doses that cause problems. KPV rests on murine colitis models and cell work such as the 2008 Gastroenterology paper, and TB-500 on the healthy-volunteer study above. See is BPC-157 safe.

Stinging at the site is more common with this one than with the others. A blue or green solution and a faint temporary stain at the site are expected from the copper rather than a fault. Nausea or a metallic taste are reported and usually reflect dose. Persistent nausea and vomiting with abdominal pain or jaundice is the pattern that would indicate copper excess and warrants stopping. The research base — Pickart's work in Biomedical Research International in 2015 and the International Journal of Molecular Sciences in 2018 — is largely mechanistic and topical. Anyone with a disorder of copper handling should not be on it. See is GHK-Cu safe.

Flushing or a head-rush within minutes of dosing, vivid dreams with evening administration, headache, and increased appetite from the ghrelin-receptor components. Then the dose-signal cluster: fluid retention, joint ache, hand tingling. Glucose handling can shift, which is why fasting glucose is in the panel. Sermorelin has the longest human record here, with controlled administration studies in age-advanced adults in 1997, and a 2018 review in Sexual Medicine Reviews assessed growth hormone secretagogues as a class. See is CJC-1295 / ipamorelin safe.

Nausea, vomiting, diarrhea, constipation, reflux, burping and early fullness, concentrated in the days after a dose increase. Fatigue and headache early on, often from reduced intake rather than the drug. Hair loss is on both approved labels at 3–5% and generally tracks the rate of weight loss. Severe abdominal pain is not an adjustment symptom. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents, with human relevance undetermined, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 — which is why the intake asks about family thyroid history. Management is in GLP-1 nausea.

Site reactions, occasional headache, drowsiness or a flat feeling. Nasal formulations produce local irritation instead. Selank and semax come from Russian clinical programs — selank compared against a benzodiazepine in anxiety disorders in 2014, semax studied in ischemic stroke — and a 2021 review in the Journal of Clinical Pharmacology places selank in that context. DSIP rests on small insomnia studies from the 1980s in the Lancet and European Neurology. Anyone already in psychiatric care should have their prescriber and psychiatrist aware of each other.

PT-141 has the fullest human safety record in this catalog after the GLP-1s, described in a 2019 long-term safety paper in Obstetrics & Gynecology and a 2022 review in the Journal of Women's Health: nausea, flushing, injection-site reactions and headache, a small transient blood-pressure rise after each dose, and focal skin darkening in about 1%. Oxytocin exists as an approved injection, but that label describes intravenous obstetric use — an honest reason to say the data for how oxytocin is prescribed here is thinner than an approved label suggests.

NAD+ produces flushing, chest tightness, nausea and site stinging when it goes in quickly; the intravenous pharmacokinetic work in Frontiers in Aging Neuroscience in 2019 is the human reference point. MOTS-c has no human safety trial, only the 2015 Cell Metabolism work and later observational studies. Methylcobalamin and the B12 injections have approved-label reactions of itching, transient rash and mild diarrhea, with hypersensitivity as the serious concern and a caution in hereditary optic nerve atrophy; L-carnitine has approved-label reactions of nausea, abdominal cramps, diarrhea and a dose-related body odor, with seizures reported in people who already have a seizure disorder.